Adaptive Biotechnologies Corp ADPT Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 11, 2023 (filed on Apr 12, 2023)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,308

Price:

$8.63
Apr 10, 2023 (filed on Apr 12, 2023)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-817

Price:

$8.50
Mar 27, 2023 (filed on Mar 29, 2023)

Insider Name:

Griffin Michelle Renee

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,341

Price:

$8.49
Mar 07, 2023 (filed on Mar 08, 2023)

Insider Name:

Taylor Stacy L

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-13,387

Price:

$8.60
Mar 07, 2023 (filed on Mar 08, 2023)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-17,155

Price:

$8.60
Mar 07, 2023 (filed on Mar 08, 2023)

Insider Name:

Sood Nitin

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-9,813

Price:

$8.60
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Pellini Michael J

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Pellini Michael J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,775

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Owen Katey Einterz

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Owen Katey Einterz

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,775

Price:

--

Filings by filing date

Apr 11, 2023 (filed on Apr 12, 2023)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,308

Price:

$8.63
Apr 10, 2023 (filed on Apr 12, 2023)

Insider Name:

Adams R Mark

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-817

Price:

$8.50
Mar 27, 2023 (filed on Mar 29, 2023)

Insider Name:

Griffin Michelle Renee

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,341

Price:

$8.49
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Pellini Michael J

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Pellini Michael J

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,775

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Owen Katey Einterz

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Owen Katey Einterz

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,775

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Neupert Peter M

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Neupert Peter M

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

14,775

Price:

--
Mar 06, 2023 (filed on Mar 08, 2023)

Insider Name:

Hershberg Robert

Ownership Type:

Direct Ownership

Securities:

Stock Option (right to buy)

Nature of Transaction:

A - Grant, award or other under Rule 16b-3(d)

# or value acquired/disposed of:

23,329

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	1165 Eastlake Ave E SEATTLE WA 98109
Tel:	1-650-8251656
Website:	https://www.adaptivebiotech.com
IR:	See website

Key People

Chad M. Robins Chairman of the Board, Chief Executive Officer, Co-Founder	Julie Rubinstein President	Harlan S. Robins Co-Founder, Chief Scientific Officer
Tycho Peterson Chief Financial Officer	Francis Lo Chief People Officer	Stacy Taylor Senior Vice President, General Counsel
Sharon Benzeno Chief Commercial Office - Immune Medicine	Nitin Sood Chief Commercial Officer - MRD

Business Overview

Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on using the biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine (IM) platform combines a suite of chemistry, computational biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its clinical diagnostic product, clonoSEQ, is used for the detection and monitoring minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL). The IM business consists of two areas: IM Pharma Services and Drug Discovery. Its immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA).

Financial Overview

For the three months ended 31 March 2023, Adaptive Biotechnologies Corp revenues decreased 3% to $37.6M. Net loss decreased 8% to $57.7M. Revenues reflect Immune meidicine revenue segment decrease of 22% to $16.2M. Lower net loss reflects General and administrative - Balancing decrease of 21% to $15.4M (expense), Personnel expenses decrease of 22% to $14.5M (expense).

Employees:	790 as of Dec 31, 2022

Reporting Currency:	U.S. Dollars
Enterprise value:	$762.87M as of Mar 31, 2023
Annual revenue (TTM):	$184.34M as of Mar 31, 2023
EBITDA (TTM):	-$172.34M as of Mar 31, 2023
Net annual income (TTM):	-$195.15M as of Mar 31, 2023
Free cash flow (TTM):	-$194.84M as of Mar 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	144,311,000 as of Apr 28, 2023
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization